PD-005 Response and resistance factor candidates to HER2 targeted therapy in gastric cancer (GC)

Florian Lordick(Leipzig University), Christian Wittekind(University Hospital Leipzig), Katrin Schierle(University Hospital Leipzig), Birgit Luber(Technical University of Munich), Ivonne Haffner(Leipzig University), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Dieter Maier(Biomax Informatics (Germany)), Miriam Ahlborn(Klinikum Braunschweig), Albrecht Kretzschmar(Roche (Switzerland)), Jorge Riera‐Knorrenschild

Annals of Oncology

June 1, 2016

10.1093/annonc/mdw200.05

Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

|The Lancet|2020|4.8k

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

|Annals of Oncology|2022|1.4k